CFM
NVCT icon

Catalyst Funds Management’s Nuvectis Pharma NVCT Stock Holding History

Catalyst Funds Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-900
Closed -$5.66K – 950
2024
Q3 		$5.66K Hold
900
– – ﹤0.01% 1231
2024
Q2 		$5.7K Buy
+900
New +$6.12K ﹤0.01% 1045

Other funds holding NVCT

BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Catalyst Funds Management's NVCT Position: Q4 2024 in Review

Catalyst Funds Management sold out of Nuvectis Pharma (NVCT) in Q4 2024, closing a stake of 900 shares — an estimated $5.66K sold.

Catalyst Funds Management first reported a position in NVCT in Q2 2024 and held it in 2 quarters. The position peaked at $5.7K in Q2 2024. 31 funds tracked by Wall St. Rank hold NVCT as of Q4 2024.

  • Catalyst Funds Management reported no remaining Nuvectis Pharma position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 900 Nuvectis Pharma shares in Q4 2024, an estimated $5.66K.
  • Catalyst Funds Management first reported a position in Nuvectis Pharma in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Nuvectis Pharma position peaked at $5.7K in Q2 2024.
  • 31 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.